

LICIT Solution raises Series A to accelerate sustainable antimicrobial innovation

LICIT Solutions completes Series A financing to accelerate the development and commercialization of next-generation sustainable active ingredients for hygiene, preservation, and protective applications LICIT Solutions GmbH, a spin-out from the Institute for Clinical Anatomy and Cell Analysis at the University of Tübingen, has successfully completed its Series A financing round. The round was led by ICIIG Ventures, joined by Next Thursday GmbH, a syndicate of business angels, Startup BW Innovation Fonds GmbH & Co. KG, managed by Mittelständische Beteiligungsgesellschaft Baden-Württemberg (MBG), LBBW Venture Capital, and Chancenkapital Biberach. The financing was further supported by the InnoGrowth BW program of L-Bank.

The investors are enthusiastic about LICIT's potential. Dr. Pelin Yilmaz, Investment Director at ICIIG Ventures, commented: "We are pleased to reaffirm our commitment to LICIT Solutions as they advance towards broader market adoption. Their technology continues to demonstrate strong potential to redefine standards in the microbial control sector, combining efficacy with a compelling safety profile." Dr. Josef Walek, Investmentmanager at MBG emphasized the market opportunity: "The growing demand for environmentally friendly and less harmful biocides is driven by stricter legal regulations and growing health and environmental awareness among consumers. We see considerable market potential for a new biocide with improved environmental and health profiles." Dr. Wolfgang Klein, Managing Partner at Next Thursday GmbH added: "What convinced us is not only LICIT's breakthrough innovation but also the highly committed founding team. We are confident they have the vision and execution strength to establish a new standard in the antimicrobial space."

LICIT Solutions develops innovative preservation and antimicrobial technologies that combine regulatory foresight with scientific innovation. Its proprietary approach enables a new generation of actives that are powerful, versatile, and safe, with applications ranging from cosmetic preservation and hygiene solutions to materials and surface protection, as well as fixation and preservation solutions for anatomy, histology, and embalming.

LICIT's flagship innovation, Aminolipin®, is a novel active substance with broad-spectrum antimicrobial activity, designed for high safety, biodegradability, and compatibility. Complementary products include Innolipin® for cosmetic preservation and INNOBALM® for advanced fixation solutions in anatomy and histology. "This Series A financing marks a pivotal milestone for LICIT," said Dr. Corinna Gleiser, CEO of LICIT Solutions GmbH. "We are delighted with the strong investor consortium and their support in bringing our sustainable antimicrobial innovations to market."

About LICIT Solutions GmbH

Founded in 2021 as part of the concluded GO-Bio project, LICIT Solutions GmbH is a spin-out of Professor Hirt's Institute for Clinical Anatomy and Cell Analysis at the University of Tübingen, Germany. LICIT specializes in developing unique antimicrobial solutions for various industrial applications.

Press release

05-Nov-2025

Source: LICIT Solutions GmbH

Further information

► LICIT Solutions
GmbH

